Baxalta’s ONIVYDE NAPOLI-1 Study Sends It to Top of Large-Caps
XLV Gets Stronger with Large-Cap Holdings Gains
XLV’s large-cap makes small gains
The large-cap stocks of the Health Care Select Sector SPDR ETF (XLV) rose marginally with a return of 0.4% on November 24, 2015. XLV’s large-caps outperformed XLV as well as the SPDR S&P 500 ETF (SPY), with returns of 0.3% and 0.15%, respectively.
XLV’s 49 large-cap stocks account for ~98.3% of XLV’s portfolio. Of the 49 large-cap stocks, 21 ended up in the red, and 28 gave positive returns. XLV’s large-caps include stocks such as Bristol-Myers Squibb (BMY), Thermo Fisher Scientific (TMO), and AbbVie (ABBV), which returned -0.25%, 0.25%, and -0.05%, respectively.
The above graph reflects the performance of XLV’s large-cap stocks compared to XLV and SPY. So far in November, XLV’s large-cap stocks have outperformed XLV and SPY. XLV’s large-cap stocks returned 1.1%, XLV returned 0.3%, and SPY returned 0.75%.
Baxalta announced data on ONIVYDE NAPOLI-1 study
Baxalta (BXLT) rose 6.4% as it announced the publication of its ONIVYDE NAPOLI-1 study in The Lancet. According to the press release, BXLT and Merrimack Pharmaceuticals (MACK) announced that The Lancet had published the article “Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI -1): a global, randomised, open-label phase 3 trial” online in advance of the print issue. The Lancet is considered one of the most prestigious peer-reviewed general medical journals in the world.
BXLT closed at $35.67 and surpassed the 100-day and 50-day moving average prices of $34.09, and $33.55, respectively. BXLT’s trading volume surged on November 25, 2015, with ~7.1 million shares being traded compared to the five-day average trading volume of ~2.3 million shares per day. BXLT has a book value of $5.87 per share. With its current price, BXLT is trading at a price-to-book value (or PBV) of 6.07x. BXLT has a weight of 0.7% in XLV’s portfolio.
Browse this series on Market Realist:
